Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP-35454 first-in-human single and multiple ascending dose study in healthy postmenopausal women
NL-OMON42209Phase 1Active, not recruiting
- Sponsor
- Shinpoong Pharma
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SP-35454 in postmenopausal osteoporosis (2 arms), sponsored by Shinpoong Pharma. Primary endpoints: Safety and tolerability, Pharmacokinetics of SP-35454 and SP-35454M8 and 4 more. Started Mar 2015; status: active, not recruiting.
02
Drugs
SP-35454
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NL-OMON42209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42209.